Hyperlipidemia

Primary Care - Clinics in Office Practice

Volumn 32, Issue 4, 2005, Pages 1027-1055

  Eaton, Charles B ^a,b  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; AMIODARONE; ATORVASTATIN; BILE ACID SEQUESTRANT; CHYLOMICRON; CORTICOSTEROID; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MACROLIDE; MEVINOLIN; NEFAZODONE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; TAMOXIFEN; TORCETRAPIB; UBIQUINONE; VERAPAMIL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; WARFARIN;

ABDOMINAL CRAMP; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; APHERESIS; ATHEROGENIC DYSLIPIDEMIA; ATHEROSCLEROSIS; AUTOSOMAL DISORDER; AUTOSOMAL DOMINANT INHERITANCE; BLOATING; BROAD BAND DYSLIPOPROTEINEMIA; CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIET RESTRICTION; DISEASE SEVERITY; DRUG FATALITY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; ENZYME DEFICIENCY; FAMILIAL COMBINED HYPERLIPIDEMIA; FAMILIAL DEFECTIVE APOPROTEIN B 100; FAMILIAL DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPOLIPOPROTEINEMIA; FOLLOW UP; FOOD DRUG INTERACTION; GALLSTONE; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HEART INFARCTION; HEART TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAPOLIPOPROTEINEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOALPHALIPOPROTENEMIA; HYPOLIPOPROTEINEMIA; INSULIN RESISTANCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LECITHIN CHOLESTEROL ACETYLTRANSFERASE DEFICIENCY; LIMB MALFORMATION; LIPOPROTEIN METABOLISM; LIVER DYSFUNCTION; LIVER TOXICITY; MIXED LIPID DISORDER; MOTIVATION; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; PANCREATITIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SITOSTEROLEMIA; SLEEP DISORDER; TANGIER DISEASE; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; VIRAL GENE THERAPY;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL, VLDL; DIET, FAT-RESTRICTED; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; LIPOPROTEIN(A); PRACTICE GUIDELINES; PRIMARY HEALTH CARE; TRIGLYCERIDES;

EID: 28444450087     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2005.09.002     Document Type: Review

References (33)

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. NIH Publication No. 02-5125 2002 US Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute Bethesda (MD)
2. S.M. Grundy, J.I. Cleeman, and N.B. Merz Implications of recent clinical trials for the National Cholesterol Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
3. U.C. Broedl, H.C. Geiss, and K.G. Parhofer Comparison of current guidelines for primary prevention of coronary heart disease: risk assessment and lipid-lowering therapy J Gen Intern Med 18 2003 190 195
4. A.L. Gould, J.E. Rossouw, and N.C. Santanello Cholesterol reduction yields clinical benefit: impact of statin trials Circulation 97 1998 946 952
5. H.B. Brewer Increasing HDL cholesterol levels N Engl J Med 350 2004 1491 1494
6. R.W. St. Clair Biology of atherosclerosis T.A. Pearson M.H. Criqui R.V. Luepker Primer in preventive cardiology 1994 American Heart Associaton 17
7. A.A. Alsheikh-Ali, J.T. Kuvin, and R.H. Karas High-density lipoprotein cholesterol in the cardiovascular equation: does the "good" still count? Atherosclerosis 180 2005 217 223
8. I. Shai, E.B. Rimm, and S.E. Hankinson Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: implications for clinical guidelines Circulation 110 2004 2824 2830
9. P.O. Kwiterovich Jr. Beyond cholesterol. The Johns Hopkins complete guide for avoiding heart disease 1989 The Johns Hopkins Press Baltimore (MD)
10. R. Williams, S.C. Hunt, and M.C. Schumacher Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics Am J Cardiol 72 1993 171 176
11. B.R. Gordon, E. Stein, and P. Jones Indications for low-density lipoprotein apheresis Am J Cardiol 74 1994 1109 1112
12. J.J. Genest, J.R. McNamara, and J.M. Ordovas Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease J Am Coll Cardiol 19 1992 792 802
13. S.M. Grundy, H.B. Brewer, and J.I. Cleeman Definition of metabolic syndrome: report of the National Heart Lung Blood Institute/American Heart Association conference on scientific issues related to definition Arterioscler Thromb Vasc Biol 24 2004 e13 e19
14. R. Pasternak, S.C. Smith, and C.N. Bairey-Merz ACC/AHA/NHLBI clinical advisory on the use and safety of statins Stroke 33 2002 2337 2341
15. V.G. Athyros, A.A. Papageorgiou, and H.A. Hatzikonstandinou Safety and efficiacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia Am J Cardiol 80 1997 608 613
16. D.R. Illingworth, E.A. Stein, and Y.B. Mitchel Comparative effects of lovastatin and niacin in primary hypercholesterolemia, a prospective trial Arch Intern Med 154 1994 1586 1595
17. A. Garg, and S.M. Grundy Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus JAMA 264 1990 723 726
18. M. Brousseau, E. Schaefer, and M. Wolfe Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
19. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
20. GISSI-Prevenzione investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial Lancet 354 1999 447 455
21. M. Grossman, D.J. Rader, and D.W. Muller A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia Nat Med 1 1995 1148 1154
22. G.C. Fonarow, and A. Gawlinksi Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles Am J Cardiol 85 2000 10A 17A
23. E.M. Antman, D.T. Anbe, and P.W. Armstrong AHA/ACC guidelines for the management of patients with ST-elevation myocardial infarction Circulation 110 2004 588 636
24. R. Collins, J. Armitage, and S. Pavish MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial Lancet 361 2003 2005 2016
25. Randomized trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
26. F.M. Sacks, M.A. Pfeffier, L. Moye for the Cholesterol and Recurrent Events Trial investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
27. D. Hunt, P. Young, and J. Simes Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial Ann Intern Med 134 2001 931 940
28. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomized placebo-controlled trial Lancet 360 2002 7 22
29. J. Shepard, G.J. Blauw, and M.B. Murphy PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Prospective Study of Pravastatin in the Elderly at Risk Lancet 360 2002 1623 1630
30. R.N. Lamaitre, B.M. Psaty, and S. Heckbert Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the cardiovascular health study Arch Intern Med 162 2002 1395 1400
31. K.A. Eagle, E. Kline-Rodgers, and S.G. Goodman Adherence to evidence-based therapies after discharge from acute coronary syndromes: an ongoing prospective, observational study Am J Med 117 2004 130 132
32. J.J. Ellis, S.R. Erickson, and J.G. Stevenson Suboptimal statin adherence and discontinuation in primary and secondary populations J Gen Intern Med 19 2004 638 645
33. R.W. Grant, K.M. O'Leary, and J.B. Weilburg Impact of concurrent medication use on statin adherence and refill persistence Arch Intern Med 164 2004 2343 2348